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Abbreviations 
aDMA, asymmetric dimethylarginine 
AdOx, adenosine 2’, 3’-dialdehyde 
AFPs, autofluorescent proteins  
EGFP, enhanced green fluorescence protein 
FMRP, fragile X mental retardation protein 
FRAP, fluorescence recovery after photobleaching 
FXR1P, fragile X related 1 mental retardation protein 
GFP, green fluorescent protein  
Dcp1a, decapping protein factor 1a 
eIF2, eucaryotic initiation factor 2 
PRMT, protein arginine methyltransferase 
RBP, RNA binding protein 
RNA interference, RNAi 
sDMA, symmetric dimethylarginine 
TIA1, T-cell internal antigen 1 
tM1, tM2, thresholded Manders coefficients N
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Summary 
Overexpressed EGFP-FMRP has been used as a substitute for endogenous fragile X 
mental retardation protein (FMRP) in protein-protein interaction studies, and in studies 
concerning the composition, the formation and the localization of neuronal granules.  
However, the question of whether this tool truly recapitulates the properties of the 
endogenous protein has not been addressed.  Here we demonstrate that overexpressed 
EGFP-FMRP forms three distinct granule types based on colocalization with various 
marker proteins.  The majority of EGFP-FMRP-containing granules are larger and more 
amorphous than known granule types.  Consistent with this, there is only partial 
colocalization with stress granule or P-body markers and no colocalization with a 
putative Drosophila ortholog neuronal granule marker.  Nevertheless, agents such as 
arsenite and hippurstanol, which create endogenous stress granules and P-bodies, drive 
EGFP-FMRP into such granules.  Additionally, whereas inhibiting cellular methyl-
protein formation alters the composition of endogenous FMRP-containing stress 
granules, we found that such treatment had little effect on the formation of EGFP-FMRP 
granules, or their composition.  Altogether these data suggest that many overexpressed 
EGFP-FMRP granules represent proto-stress granules requiring external stimuli for their 
conversion.  More importantly, the inherent heterogeneity of these granules suggests that 
caution should be used in extrapolating results obtained with EGFP-tagged surrogates of 
FMRP to endogenous FMRP granules. 
Key words: EGFP, FMRP, stress granules, P-bodies, protein arginine methylation 
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Introduction 
 Autofluorescent protein tags (AFPs) have been widely used as tools to study a 
variety of biological processes including, nervous system development (Brand, 1999), 
developmental abnormalities (Detrich III, 2008), neural stem cell development (Encinas 
and Enikolpov, 2008), localization of proteins in specific organelles (Di Giorgi et al., 
1999), protein-protein interactions (Kedersha et al., 2005), protein-RNA interactions 
(Rackham and Brown, 2004), protein (Pierce and Vale, 1999) and mRNA trafficking 
(Querido and Chartrand, 2008), and membrane dynamics (Lippincott-Schwartz et al., 
1999).  Green fluorescent protein (GFP) and the myriad of spectral variants comprising 
the AFPs are relatively small proteins Mr 27, but are much larger than many other widely 
used tags.  As such, it is imperative to demonstrate that the AFP tag does not alter the 
transport, the localization or the functional properties of the protein being tagged 
(Lippincott-Schwartz et al., 1999).  For example, Ozlu et al used RNA interference 
(RNAi) in combination with a TXL-1-GFP fusion to demonstrate that the transgene could 
functionally replace endogenous TXL-1 at the centrosome (Özlü et al., 2005).  On the 
other hand, there appears to be a significant discrepancy between the localization of 
endogenous P58
TFL
 with endogenous P-body markers and that of GFP- P58
TFL
 and 
transfected P-body markers, suggesting that the fusion protein may not adequately mimic 
the endogenous form (Bloch and Nobre, 2010; Minagawa et al., 2009; Minagawa and 
Matsui, 2010). 
 The fragile X mental retardation protein, FMRP, is a RNA binding protein that 
plays an important role in controlling translation in neurons (Bassell and Warren, 2008).  
Studies by a number of laboratories have demonstrated that endogenous FMRP associates 
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with macromolecular granules in the brain, in the neurites of cultured neuronal cells and 
in the cell bodies of non-neuronal cells (Aschrafi et al., 2005; Didiot et al., 2008; 
Dolzhanskaya et al., 2006a; Dolzhanskaya et al., 2006b; Kanai et al., 2004; Xie et al., 
2009).  Immunofluorescence studies have shown that these granules tend to be small and 
not that prevalent.  In contrast, AFP-tagged FMRPs have been used by a number of 
laboratories to assess various questions concerning neuronal granule make up and 
dynamics (Antar et al., 2005; Barbee et al., 2006; Castren et al., 2001; Cziko et al., 2009; 
Darnell et al., 2005; De Diego Otero et al., 2002; Dictenberg et al., 2008; Levenga et al., 
2009; Ling et al., 2004; Pfeiffer and Huber, 2007).  These granules tend to be much larger 
than endogenous FMRP granules and also much more prevalent in dendrites.  However, 
the question of what type(s) of granules AFP-FMRP represents has not been adequately 
addressed. 
 Here we have examined EGFP-FMRP expression in HeLa cells using a 
variety of known granule marker proteins and under various conditions known to induce 
the formation of specific granule types or modulate their composition.  Our studies 
demonstrate that EGFP-FMRP granules fall into at least three different functional classes, 
the majority of which appears to be a proto-stress granule.  The implications of these 
results are discussed. 
Results 
EGFP-FMRP expression results in a heterogeneous array of granules  
 Fluorescence microscopy of primary hippocampal neurons and Neuro 2A cells 
transfected with a plasmid encoding an EGFP-FMRP fusion protein has shown that its 
expression was in the form of granules that were confined largely to the cytoplasm (Antar 
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et al., 2004; Darnell et al., 2005; Pfeiffer and Huber, 2007).  Here we show that HeLa 
cells transfected with the same plasmid express fluorescent granules with an assortment 
of sizes.  In contrast, transfection of the parent vector shows that EGFP exhibits diffuse, 
non-granular cytoplasmic expression, Fig. 1A.  Analysis of the distribution of EGFP-
FMRP granules reveals that they fall into three different size categories (small, 
intermediate and large), Fig. 1B.  In contrast, endogenous FMRP granules were much 
more homogeneous and mainly correspond in size to the smaller size EGFP-FMRP 
granules, Fig. 1C.  These data are consistent with two competing hypotheses.  One 
possibility is that individual EGFP-FMRP granules have disparate compositions and 
possibly differing functions.  The other likelihood is that the population of EGFP-FMRP 
granules represents nascent core particles of the same composition, but with differing 
aggregation states. 
EGFP-FMRP expression and stress granule markers 
Previous studies have shown that endogenous FMRP forms a variety of granule 
types including stress granules.  Stress granules can be formed in response to heat shock 
(Mazroui et al., 2002), oxidative stress (Thomas et al., 2004), RNA binding protein over 
expression (Solomon et al., 2007), expression of a phosphomimetic mutant form of  
eukaryotic initiation factor 2 (eIF-2) (McEwen et al., 2005) and interfering with eIF4A 
activity (Mazroui et al., 2006).  To determine whether the granules formed by expression 
of EGFP-FMRP were stress granules, rat pheochromocytoma cells (PC12) were 
transiently transfected with an EGFP-FMRP expression vector.  Twenty four hours later 
the cells were immunostained with anti-TIA1, an RNA binding protein which detects 
core stress granules (Kedersha et al., 2005), and then visualized by confocal microscopy.  
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As shown in Fig. 2 (panel a), punctate EGFP-FMRP expression was observed in the 
cytoplasm of PC12 cells.  In contrast, but as expected, TIA1 was found in both the 
cytoplasm and the nucleus, Fig. 2 (panel b).  In the cytoplasm TIA1 and EGFP-FMRP co-
localized in large perinuclear granules; however, there were a host of smaller EGFP-
FMRP granules that did not contain TIA1.  This general pattern of incomplete co-
localization was also observed in HeLa cells expressing EGFP-FMRP, Fig. 2 (panels d-i).  
Nevertheless, it did not appear that granule size was a determining factor in the co-
localization of TIA1 and EGFP-FMRP, rather there appeared to be cells with extensive 
co-localization, and cells with poor co-localization (compare panels d-f with g-i).  
However, overall cells exhibiting colocalization were in the minority (see below).  
Interestingly, in the latter cells, TIA1 was largely found in the nucleus.   
To quantify the extent of colocalization between EGFP-FMRP and TIA1 we 
performed colocalization analyses.  By manually masking nuclear staining and setting 
threshold limits on each fluorescence channel we were able to differentiate granular 
versus non-granular staining.  Table 1 shows the thresholded Manders coefficients tM1 
(fraction of red in the green channel) and tM2 (fraction of green in the red channel) for 
the EGFP-FMRP granules under different conditions.  In the absence of treatment the 
majority of EGFP-FMRP granules were devoid of TIA1; however, following treatment 
with either sodium arsenite or hippurstanol there was a significant shift of TIA1 into 
these granules.   
We next examined colocalization between EGFP-FMRP granules and another 
stress granule marker, FXR1P.  Endogenous FXR1P extensively colocalizes with 
endogenous FMRP in arsenite induced stress granules (Dolzhanskaya et al., 2006a; 
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Dolzhanskaya et al., 2006b), Fig. 3A (panel c).  However, as shown in Fig. 3B (panels d-
f), colocalization between EGFP-FMRP granules and FXR1P was also incomplete.  
Again however, in the presence of arsenite EGFP-FMRP granules almost completely 
colocalized with FXR1P, Fig. 3C (panel i). 
Do EGFP-FMRP granules contain phospho-eIF2? 
There are two distinct mechanisms that initiate stress granule formation, both of 
which involve blocking translational initiation.  Environmental stresses such as heat 
shock, osmotic shock and oxidative stress produce stress granules via phosphorylation of 
eukaryotic initiation factor 2 (p-eIF2) (Kedersha et al., 2007; Lu et al., 2001).  On the 
other hand, stress granules can also be induced via an eIF2-independent pathway by 
blocking cap-dependent initiation during poliovirus infection (Mazroui et al., 2006; 
White et al., 2007).  As phosphorylated eIF2 can associate with stress granules (Kimball 
et al., 2003), we next determined whether EGFP-FMRP granules contained 
phosphorylated eIF2; the results are shown in Fig. 4A.  Phospho-eIF2 was weakly and 
diffusely localized within the cytoplasm of HeLa cells.  Significantly, the staining 
intensity of both EGFP-FMRP expressing cells and non-expressing cells were equivalent, 
implying that the expression of EGFP-FMRP does not markedly increase phospho-eIF2 
expression.  Consistent with this there is little colocalization with EGFP-FMRP granules, 
Fig. 4A (panel c).  In contrast, arsenite-induced TIA1-containing stress granules did 
exhibit some colocalization with phospho-eIF2; however, the phospho-eIF2-granules 
were much smaller than the TIA1-stress granules, Fig. 4B (panel f), indicating that they 
were associated with the granules rather than core constituents.  
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Hippuristanol a natural product derived from Isis hippuris inhibits eIF4A, and by 
doing so induces stress granule formation (Lindqvist et al., 2008).  We next determined 
the effect hippuristanol had on EGFP-FMRP granule formation.  As shown in Fig. 5A 
(panel b) hippuristanol induced a robust formation of TIA1-containing stress granules in 
both EGFP-FMRP-expressing cells and in EGFP-FMRP-nonexpressing cells.  In EGFP-
FMRP-expressing cells, TIA1 and EGFP-FMRP colocalized extensively Fig. 5A (panel 
c) and Table 1.  In contrast, we observed no colocalization with phospho-eIF2; Fig. 5A 
(panels d-f). 
In the absence of hippuristanol, EGFP-FMRP-nonexpressing cells exhibited few 
TIA1 granules, whereas EGFP-FMRP-expressing cells more often exhibited colocalizing 
TIA1 granules, Fig. 5B (panel i).  However, as with the experiments shown in Fig. 2, 
there were also many instances of EGFP-FMRP-expressing cells that were devoid of 
TIA1 granules, Table 1.  In addition, phospho-eIF2 and EGFP-FMRP did not colocalize 
in the absence of hippurstanol, Fig. 5B (panel l). 
EGFP-FMRP granules and the P-body marker Dcp1a 
 P-bodies are another type of granule, distinct from, but associated with stress 
granules (Anderson and Kedersha, 2006).  Studies have shown that certain proteins 
shuttle between stress granules and P-bodies, while others do not, marking them as core 
constituents (Kedersha et al., 2005).  The decapping factor, Dcp1a, is a core constituent 
of P-bodies (Cougot et al., 2004).  To determine whether EGFP-FMRP was associated 
with P-bodies HeLa cells were transiently transfected with an EGFP-FMRP expression 
vector.  Twenty four hours later the cells were immunostained with anti-Dcp1a and 
visualized by confocal microscopy.  Fig. 6A (panel c) shows that EGFP-FMRP granules 
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can occasionally overlap with Dcp1a-containing granules, indicating that a portion of 
EGFP-FMRP is present in P-bodies.  Quantitative colocalization analyses reveal 
however, that like the stress granule markers, the extent of colocalization is very weak, 
Table 1.  Treating cells with sodium arsenite for 20 min following transfection produces 
stress granules and P-bodies (Kedersha et al., 2007).  Under these conditions Dcp1a 
granules associate more closely with EGFP-FMRP granules, although they generally do 
not overlap, Fig. 6B (panel f) and Table 1.  In this respect, Dcp1a mimics Hsp70c, Fig. 
6C (panel l).  
Thus, exogenously expressed EGFP-FMRP sorts into at least three granule types: 
stress granules, P-bodies and a unique granule, which represents the largest fraction of 
this set.   
The physical characteristics of EGFP-FMRP granules differ from stress granules and P-
bodies 
To further characterize EGFP-FMRP granules we undertook morphometric 
analyses of two readily quantifiable features, granule shape and granule size.  The results 
were compared to arsenite-induced TIA1 granules, hippuristanol-induced TIA1 granules 
and endogenous Dcp1a-containing P-bodies.  As expected, we found that the Dcp1a-
containing P-bodies were significantly smaller than arsenite-induced stress granules 
hippuristanol-induced stress granules, and EGFP-FMRP granules.  On the other hand, 
EGFP-FMRP granules were both substantially larger and more amorphous than the other 
granules, Table 2.  These data again highlight differences between EGFP-FMRP granules 
and other granule types.  
The dynamic properties of EGFP-FMRP granules mimic stress granules  
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Emetine inhibits protein synthesis elongation (Gay et al., 1989; Grollman and 
Huang, 1976; Yamasaki et al., 2007) altering the dynamic equilibrium between 
polyribosomes and stress granules.  Kedesha et al found that in DU-145 cells treated with 
arsenite the addition of emetine at concentrations that inhibit protein synthesis effectively 
“dissolved” TIA1-containing stress granules (Kedersha et al., 2000).  Therefore, we used 
emetine to assess the dynamic interrelationship between EGFP-FMRP-containing 
granules and polyribosomes.  We first demonstrated that endogenous TIA1 stress 
granules and endogenous FMRP stress granules in HeLa cells treated with arsenite are 
substantially altered by emetine, Fig. 7A.  Specifically, the sizes of the granules in the 
emetine-treated cells were much smaller than the arsenite-induced stress granules, Fig. 
7B-C.  We then applied this paradigm to assess the effect of emetine on EGFP-FMRP 
granules.  Here we found that both untreated EGFP-FMRP granules and arsenite-treated 
EGFP-FMRP granules responded to emetine in much the same way as TIA1 and FMRP 
stress granules, Fig. 8A-C.   
Fluorescence recovery after photobleaching is a method that is often used to 
characterize the dynamic properties of granules (Kedersha et al., 2005; Kedersha et al., 
2008).  For example, Antar et al examined the effect nocodazole had on EGFP-FMRP 
granules in cultured hippocampal neurons (Antar et al., 2005) and found their transport 
within dendrites was microtubule-dependent.  Here we performed similar analyses on 
EGFP-FMRP granules comparing them to ones formed following arsenite treatment.  In 
the absence of treatment EGFP-FMRP granules exhibited a range of motilities.  Some 
granules were quite stationary, while others were highly mobile.  FRAP analysis of these 
granules in the absence of treatment revealed they recovered 50% of their unbleached 
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intensity within 10 minutes, implying that there is a dynamic exchange between non-
granular EGFP-FMRP and the granules, Fig. 9A-C.  To determine whether conditions 
that induce the formation of stress granules alters the recovery of EGFP-FMRP granules, 
HeLa cells were treated with arsenite and FRAP was performed on the resulting 
perinuclear granules.  The results showed that the treatment increased the rate of recovery 
slightly, but not significantly, Fig. 9D. 
EGFP-FMRP granules contain methylated proteins, but do not require methylated 
proteins for their formation 
 Previously we showed that endogenous FMRP-containing stress granules contain 
asymmetric dimethylarginine-modified proteins (aDMA-proteins) and that the cell’s 
methylation state affected their composition (Dolzhanskaya et al., 2006a).  To examine 
the effect inhibiting cellular protein methylation had on the formation and distribution of 
EGFP-FMRP granules, HeLa cells transiently expressing EGFP-FMRP were treated for 
twenty four hours with the general methylation inhibitor adenosine 2’, 3’-dialdehyde 
(AdOx).  Subsequently, the cells were immunostained with anti-TIA1 and visualized by 
confocal microscopy.  As was the case in the untreated cells (Fig. 2) there appeared to be 
EGFP-FMRP-expressing cells that had extensive colocalization with TIA1 and cells that 
had relatively little colocalization.  Therefore, the cell’s protein methylation state appears 
to have little effect upon the interaction of EGFP-FMRP and TIA1.  
 We next examined whether EGFP-FMRP granules contained asymmetrically 
dimethylated (aDMA) proteins.  HeLa cells, transiently expressing EGFP-FMRP were 
incubated in the absence or presence of AdOx for twenty-four hours (as above).  
Subsequently, the cells were immunostained with two antibodies that detect different sets 
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of aDMA proteins.  For the untreated cells, cytoplasmic EGFP-FMRP granules exhibited 
extensive colocalization with the proteins detected by these two antibodies, Fig. 10A 
(panels a-c and f-h).  Importantly, AdOx treatment resulted a marked reduction in 
immunoreactivity, both overall and in the granules, Fig. 10A (panels c-e and i-k), 
indicating that the staining was indeed due to aDMA proteins.  Quantitative analyses 
showed that under the conditions used the extent of the reduction was ca. 50 %, Fig. 10B.   
The above data suggested that reduced methylation of endogenous proteins does 
not drastically alter the composition of EGFP-FMRP granules; however, it does not 
inform one as to whether asymmetric dimethylation affects the formation of EGFP-
FMRP granules.  To address this question, HeLa cells were pre-treated with AdOx for 
twenty-four hours prior to transfection.  Subsequently, the cells were transfected with the 
EGFP-FMRP expression vector in AdOx-containing media.  As shown in Fig. 11A, 
EGFP-FMRP granules were readily detected even in the continued presence of AdOx 
implying that full protein methylation is not required for the formation of these granules.  
In concert with these data treatment with AdOx had no effect on the distribution of 
EGFP-FMRP granules, Fig. 11B.   
We next assessed whether EGFP-FMRP granules contained symmetrically 
dimethylated (sDMA) proteins.  In the absence of treatment we found that the 
symmetrically dimethylated protein immunoreactivity localized primarily to the nucleus, 
Fig. 12A (panel b).  Notably, the cytoplasmic staining partially associated with EGFP-
FMRP granules, indicating that these granules are heterogeneous with respect to sDMA-
containing proteins.  However, treating the cells with arsenite following transfection 
resulted in the recruitment of a significant amount of sDMA proteins into cytoplasmic 
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granules, and in EGFP-FMRP expressing cells; almost all of the EGFP-FMRP granules 
contained sDMA-modified proteins, Fig. 12A (panels g-i).  Treating the cells with AdOx 
prior to arsenite treatment significantly decreased the sDMA protein immunoreactivity 
(Fig. 12A panel k and Fig. 10B) although the extent of colocalization with EGFP-FMRP 
granules was unchanged, Fig. 12B.   
Consistent with the immunostaining results, Western blot analyses showed that 
AdOx treatment decreased the amount of aDMA and sDMA in various proteins, albeit to 
different extents.  In contrast, the expression of five different protein arginine 
methyltransferases (PRMTs) was unaffected by treatment with AdOx, Fig. 13.   
As these data unequivocally demonstrate sDMA is harbored in arsenite-treated 
EGFP-FMRP granules we next endeavored to ascertain whether endogenous stress 
granules also contained sDMA-modified proteins.  To this end we treated HeLa cells with 
arsenite and then immunostained them with antibodies to TIA1 and sDMA.  We observed 
significant colocalization between sDMA-modified proteins and TIA1-containing stress 
granules, Fig. 14. 
Identities of sDMA-modified proteins in Stress Granules 
Anti-SYM10 is a well-characterized antibody, which primarily detects proteins 
associated directly or indirectly with pre-mRNA splicing (Boisvert et al., 2003a).  In 
particular, the Sm proteins (SmB/B’, SmD1/D3, and U6 small nuclear RNA-associated 
Sm-like proteins Lsm4 and Lsm8) have been shown to contain symmetric 
dimethylarginine (Brahms et al., 2001) and are known epitopes for SYM10 (Boisvert et 
al., 2002).  Cziko et al have shown that the smD3 gene dominantly suppresses the sev-
dfmr1 rough-eye phenotype, and the encoded protein, SmD3, partially co-localizes with 
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YFP-dFmr1 in larval ventral ganglion cell neuronal granules (Cziko et al., 2009).  
Therefore, it was of interest to determine whether EGFP-FMRP or endogenous FMRP 
colocalized with human SmD3.  We found, in contrast to the heterologous YFP-dFmr1 
variant that human SmD3 did not colocalize with endogenous FMRP granules, FMRP 
arsenite-induced stress granules, TIA1 arsenite-induced stress granules, or with EGFP-
FMRP granules, Fig. 15A-C, nor did they colocalize with another Sm subtype, SmB/B’, 
Fig. 16. 
PRMT3 localizes to Stress Granules 
The localization of both aDMA-modified proteins and sDMA-modified proteins 
in stress granules led us to wonder whether any of the PRMTs also colocalize with these 
granules and potentially control their composition.  Because of its known association 
with ribosomes (Swiercz et al., 2007), we were particularly attracted by the possibility 
PRMT3 might be found in stress granules.  Therefore, we measured the subcellular 
distribution of PRMT3 in the presence and absence of arsenite treatment by confocal 
immunofluorescence microscopy using endogenous FXR1P as a stress granule marker.  
We found that in the presence of arsenite PRMT3 was found in perinuclear cytoplasmic 
granules that colocalized with FXR1P stress granules, Fig. 17.  Interestingly, pre-
treatment of the cells with AdOx resulted in the relocation of most of PRMT3 to the 
nucleus, effectively eliminating the colocalization.  (The basis of this effect is currently 
unknown).  In contrast, we found that neither class II PRMT (PRMT5 nor PRMT7) 
colocalized with TIA1-containing stress granules.    
Discussion 
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Heterologously expressed EGFP-FMRP has been used as a surrogate marker for 
endogenous FMRP by several laboratories in a wide variety of studies (Antar et al., 2005; 
Castren et al., 2001; Cougot et al., 2008; Darnell et al., 2005; Davidovic et al., 2004; De 
Diego Otero et al., 2002; Dictenberg et al., 2008; Levenga et al., 2009; Pfeiffer and 
Huber, 2007).  Like endogenous FMRP, EGFP-FMRP was found to co-sediment with 
polyribosomes in cultured neurons (Darnell et al., 2005).  Additionally, Antar et al 
showed that EGFP-FMRP was transported to dendrites in the form of granules (Antar et 
al., 2004).  Subsequent work showed that these granules associated with mRNA and 
kinesin transport motors (Wang et al., 2008) and were responsive to stimulation by the 
mGluR agonist DHPG.  These too are properties of endogenous FMRP (Hou et al., 2006; 
Kanai et al., 2004).   
However, important questions regarding EGFP-FMRP remained to be addressed.  
Were these granules uniformly composed?  Did they correspond to one or more types of 
known granules?  Could they be modified by various treatments that are known to affect 
the formation and/or composition of known granule types?  Answering these questions in 
light of the well-established properties of endogenous FMRP granules (Didiot et al., 
2008; Dolzhanskaya et al., 2006a; Dolzhanskaya et al., 2006b) was one of the objectives 
of this study. 
In contradistinction to endogenous FMRP granules, which are small, and while 
pervasive in cultured cells not particularly prevalent, (Cougot et al., 2008; Dolzhanskaya 
et al., 2006a; Dolzhanskaya et al., 2006b) EGFP-FMRP granules are large, and 
amorphous.  In fact, they tend to be larger and more non-uniformly round than stress 
granules, Table 2.  Underlying this size/shape heterogeneity we found that EGFP-FMRP 
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granules also are non-uniformly composed.  Endogenous FMRP absent environmental 
stress does not colocalize with stress granule markers; however, in the presence of a 
stressor such as heat or arsenite FMRP is recruited into stress granules (Didiot et al., 
2008; Dolzhanskaya et al., 2006a; Mazroui et al., 2002).  Using well-known stress 
granule markers (TIA1 and FXR1P) we found that EGFP-FMRP granules weakly 
colocalize with these proteins in the absence of a bonafide stressor; however, stressing 
EGFP-FMRP-expressing cells with either arsenite or hippurstanol resulted in a marked 
increase in colocalization, Figs 2, 3 and Table 1.  Thus, native EGFP-FMRP granules are 
composed of at least two granule types existing in dynamic equilibrium with each other. 
Contradicting data exists regarding the association of FMRP with P-bodies.  
Several lines of evidence have shown that FMRP, or its Drosophila counterpart dFMR1, 
interact specifically with components that are associated with P-bodies (Anderson and 
Kedersha, 2006).  Ishizuka et al first demonstrated that dFMR1 interacted with Ago2 and 
the RNA helicase Dmp68 (Ishizuka et al., 2002); more recently Cheever et al showed that 
FMRP interacts with Dicer in a phosphorylation-dependent fashion (Cheever and Ceman, 
2009).  Moreover, immunofluorescence studies of rat dorsal root ganglia cultures (DRG) 
showed that endogenous FMRP partially overlapped the staining of both Ago3 and Ago4 
in rat dorsal root ganglion processes (Hengst et al., 2006), while Cougot et al and Barbee 
et al demonstrated that EGFP-FMRP and GFP-dFMR1 colocalized with Dcp1 (Barbee et 
al., 2006; Cougot et al., 2008).  Nevertheless, Didiot et al failed to observe much 
localization of endogenous FMRP with Dcp1a in HeLa cells (Didiot et al., 2008).   Here 
we found a weak colocalization between EGFP-FMRP granules and the P-body marker 
Dcp1a, Fig. 6 and Table 1.  We hypothesize that the differing results may be related to 
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differences in the species and tissue expression of P-body components (González-
González et al., 2008). 
As there are several stressors that trigger the formation of stress granules, so too 
there are at least two independent mechanisms by which they form.  Arsenite treatment 
induces the phosphorylation of eucaryotic initiation factor 2 eIF2, which sequesters a 
ternary complex between itself, initiator Met-tRNA and GTP.  This, in turn, results in the 
recruitment of the T-cell internal antigen (TIA-1), into 48S* pre-initiation complexes, 
which are then no longer competent to form 80S monosomes.  Hippurstanol, on the other 
hand, inhibits eIF4A without affecting eIF2 phosphorylation (Mazroui et al., 2006).  We 
found in both arsenite-treated and hippurstanol-treated cells that there was little 
association between phospho-eIF2 and EGFP-FMRP granules; however, arsenite-
induced TIA1-containing stress granules showed a modest colocalization consistent with 
data from other laboratories (Kedersha et al., 2002; Kimball et al., 2003).   Again, these 
data underscore fundamental differences between EGFP-FMRP granules and stress 
granules. 
We also determined whether EGFP-FMRP granules were in dynamic equilibrium 
with polyribosomes and/or the pool of non-granular cytoplasmic EGFP-FMRP by 
emetine treatment (Kedersha et al., 2000) and FRAP (Lippincott-Schwartz et al., 1999), 
respectively.  Here we found that EGFP-FMRP granules mimic the properties of 
endogenous FMRP, implying that there are certain “core characteristics” of granules that 
are invariant (Buchan and Parker, 2009). 
Like a host of other post-translational modifications (Kwon et al., 2007; Mazroui 
et al., 2007; Wasserman et al., 2009), protein methylation regulates stress granules.  In 
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particular, we have previously demonstrated that pharmacological inhibition of protein 
methylation altered the FXR1P content of FMRP-containing stress granules 
(Dolzhanskaya et al., 2006a).  Thus, it was of interest to determine the role methylation 
played in EGFP-FMRP granule formation.  We found, in contrast to endogenous FMRP, 
that EGFP-FMRP granules harbored aDMA-containing proteins, but that the 
modification of these proteins was not required for granule formation, Figs 10-11.  We 
also showed that the sDMA content of EGFP-FMRP granules was heterogeneous.  
Nevertheless, following arsenite treatment sDMA-containing proteins were recruited into 
endogenous stress granules and EGFP-FMRP stress granules, Fig. 12.  
The sDMA antibody that was used in this study was raised to the peptide 
R
sDMA
GR
sDMA
GR
sDMA
GR
sDMA
G and was previously shown to preferentially recognize 
sDMA-containing proteins (Boisvert et al., 2002).  In fact, Boisvert et al detected more 
than 29 potential sDMA-containing proteins in immunoprecipitation reactions using this 
antibody (Boisvert et al., 2003b).  Among the proteins identified in this screen and 
subsequently confirmed as harboring sDMA was the splicing-related protein SmD3.  As 
Cziko et al recently determined that GFP-dFmr1 neuronal granules partially colocalized 
with YFP-SmD3 (Cziko et al., 2009), it was of significant interest to determine whether 
human endogenous SmD3 (hSmD3) colocalized with EGFP-FMRP- or endogenous 
FMRP granules.  We found that hSmD3 failed to colocalize with endogenous FMRP or 
with EGFP-FMRP granules in the presence or the absence of stress, nor did it colocalize 
with TIA-containing stress granules, Fig. 15.  These results agree with the findings of 
Zhang et al who demonstrated that the neurites of mouse primary motor neurons were 
deficient in endogenous Sm proteins although they contained significant amounts of 
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SMN granules (Zhang et al., 2006).  Subsequent work by Piazzon et al has shown that 
FMRP-containing SMN complexes are also devoid of Sm proteins (Piazzon et al., 2007).  
More importantly however, the data underscore the potential difficulties of using over 
expressed AFP-proteins as markers of endogenous proteins and of extrapolating results of 
protein ortholog studies. 
The localization of both sDMA-modified proteins and aDMA-modified proteins 
in stress granules led us to wonder whether any of the PRMTs also colocalize with these 
granules and potentially control their composition.  Precedence for this can be found in 
the fact that many PRMTs act in complexes to regulate transcription (Chen et al., 2002).  
More importantly, post-translational regulation of stress granules is emerging as an 
important, albeit little understood feature of the stress response.  Besides the effects the 
methylation inhibitor AdOx has on stress granule composition, recent work has shown 
that phosphorylation (Wasserman et al., 2009), acetylation (Kwon et al., 2007) and 
ubiquitination (Kwon et al., 2007; Mazroui et al., 2007) regulate stress granule dynamics 
via direct incorporation of the modifying enzymes.  Furthermore, it is known that 
PRMT3 uniquely associates with ribosomes and methylates ribosomal protein S2 
(Swiercz et al., 2004), and the small subunit of the ribosome is a core constituent of stress 
granules.  Thus, we were particularly attracted by the possibility PRMT3 might be found 
in stress granules.  Our findings are consistent with an association of PRMT3, but not 
PRMT5 and PRMT7 in stress granules, Fig. 17, although the ramifications of this 
observation remain to be fleshed out.   
Overall, our work has shown both similarities and marked differences between 
endogenous FMRP granules and heterologous EGFP-FMRP granules.  The similarities in 
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the various RNA binding proteins (RBPs) and translational components that are 
associated with endogenous and heterologous granules highlight the fact that granules of 
a particular class (e.g. stress granules) share a common core that is either added to or 
subtracted from to construct a granule of unique composition and function.  The 
differences between endogenous FMRP granules and heterologous EGFP-FMRP 
granules, particularly the class heterogeneity of the EGFP-FMRP granules and the fact 
that exogenous treatment can alter the compositional balance of the granule class (e.g. 
stress granule vs. non-stress granule), point to the inter-convertibility of these granules.  
Additionally, differences in the post-translational modification state of EGFP-FMRP 
granules and FMRP granules suggest that they may be uniquely regulated.  Thus, the 
post-translational, compositional and functional heterogeneity of FMRP granules (and 
probably all granules) pose tremendous challenges in our ability to understand the 
biochemistry and dynamics of their formation and of their modulation. 
Materials and Methods 
Reagents 
 Sodium arsenite, adenosine 2’, 3’-dialdehyde (AdOx) and emetine were 
purchased from Sigma.  Hippurstanol was a kind gift from Jerry Pelletier (McGill Cancer 
Center, McGill University, Montreal, Quebec, Canada). 
Plasmids and Transfection 
A mammalian expression plasmid containing an enhanced green fluorescent-
FMRP fusion protein under the control of a cytomegalovirus promoter pEGFP-FMRP 
(Antar et al., 2004) was a kind gift of Dr. Gary Bassell (Emory University, Atlanta, GA).  
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The parent vector, pEGFP-C2, was purchased from Clontech.  Cells (3 x 10
5
/35 mm dish) 
were transfected with 1 g of plasmid DNA using Lipofectamine Plus (Invitrogen). 
Proteins and antibodies 
FMRP mAb-2160, which recognizes an epitope in the N-terminus of human 
FMRP, and normal mouse serum were purchased from Chemicon.  Phospho-eIF2 pAb 
(Ser52) (KAP-CP131) and Hsp70c mAb (HSP-820) were obtained from StressGen.  
TIA1 pAb (sc-1751), FXR1P pAb (sc-10552) and SmB/B’/N pAb (sc-25372) were 
purchased from Santa Cruz.  Asymmetric dimethylarginine pAb (ASYM24) and 
symmetric dimethylarginine pAb (SYM10) were purchased from Millipore.  
Dimethylarginine pAb (mRG) was obtained from CH3 Biosystems.  Protein arginine 
methyltransferase antibody, PRMT1 was obtained from Abcam (ab70724), while PRMT3 
pAb (07-256), PRMT4 pAb (AB3345), PRMT5 pAb (07-405) and PRMT7 pAb (07-639) 
were obtained from Millipore.  SmD3 antibody (HPA001170) was purchased from 
Sigma.  hDcp1a pAb was a kind gift of J. Lykke-Andersen (University of Colorado, 
Boulder, CO). 
Cell culture 
HeLa cells were grown at 37°C in 5% CO2 and maintained in DMEM 
supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin.  In some 
cases, the cells were treated with 20 M AdOx, 0.5 mM sodium arsenite, 10 M 
hippurstanol, or with 10 g/ml emetine and processed as indicated (Dolzhanskaya et al., 
2006a). 
PC12 cells were grown at 37 °C in 5% CO2 and maintained in DMEM 
supplemented with 10% FBS and 200 mM glutamine, 100 U/ml penicillin and 100 g/ml 
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streptomycin.  In some cases, the cells were treated with 20 M AdOx or with 0.5 mM 
sodium arsenite and harvested as indicated (Dolzhanskaya et al., 2006b). 
Gene expression in cultured cells 
Western blotting was carried out according to protocols set forth by the 
manufacturer for each antibody or as previously described (Dolzhanskaya et al., 2006a).  
For immunostaining, cells were grown on poly-L-lysine coated coverslips in the presence 
or absence of 20 M AdOx and in the presence or absence of 0.5 mM sodium arsenite as 
indicated.  The cells were fixed in 2% paraformaldehyde for 10 minutes and washed with 
PBS and then blocked in (RPMI1640 base medium, 0.05 % saponin, 0.1 % sodium azide, 
2 % goat serum) for 30 minutes at room temperature. Subsequently, the cells were stained 
with antibodies to FMRP (1:500), TIA-1 (1:100), Hsp70 (1:300), FXR1P (1:50), hDcp1 
(1:200), phospho-eIF2 (1:100), ASYM24 (1:100), mRG (1:150), SmD3 (1:75) 
SmB/B’/N (1:50) or SYM10 (1:100) for 1 hour.  This was followed by incubation with 
Alexa Fluor secondary antibodies (1:500 dilution) for 30 minutes at room temperature.  
Finally, the coverslips were washed in RPMI1640 base medium, 1 % goat serum and 
mounted in buffered glycerol.  Fluorescence was detected with an Eclipse 90i dual laser-
scanning confocal microscope (NIKON).  Images were acquired at 20-100x 
magnification. 
Image analyses 
Relative EGFP-FMRP granule size (pixels
2
) was determined from select confocal 
images.  Granules in each image file were defined using the threshold function in Image J 
(http://rsb.info.nih.gov.80/ij/).  Granule areas were then calculated using the Analyze 
Particles feature.  For calculations all images were taken at 40x magnification and the 
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entire image was quantified; thereby ensuring a uniform pixel size.  The circularity of the 
granules, 4π (area/perimeter
2
), was calculated similarly.  The data were then imported 
into Excel for subsequent analysis.  For presentation, granule size distributions were all 
normalized to 500 particles and the normalized distributions were compared using the F-
test for two sample variance.  Protein co-localization measurements were performed by 
counting single- and double-stained granules of acquired images (Thomas et al., 2004).  
Co-localization was determined using the JaCoP Plugin (Bolte and Cordelieres, 2006; 
Didiot et al., 2008).  Line scans of the cellular fluorescence intensity (Biron et al., 2004) 
were also acquired using Image J software. 
FRAP 
Fluorescence recovery after photobleaching (FRAP) was measured as described by Wang 
et al with modification (Wang et al., 2008).  HeLa cells were cultured on 40 mm 
coverslips and transfected with pEGFP–FMRP.  Twenty four hours the cells were 
mounted in Sykes-Moore chambers (Bellco Glass Inc., Vineland, NJ) on a Nikon 90i 
microscope coupled to a Nikon C1 three-laser scanning confocal system (NIKON 
Instruments Inc., Melville, NY).  The cells were maintained at 37 C with an air curtain 
incubator (NevTek, Williamsville, Va).   Baseline images of EGFP-FMRP-expressing 
cells were acquired and select regions of interest (ROI) within the transfected cells were 
bleached to 10 % or less of their initial intensity with the argon laser.  Time-lapse images 
of the recovery were obtained at 30 second intervals.  Image data before and after 
bleaching was first concatenated and then converted into animated GIF files and 
processed using Image J software.  The mean fluorescence within select bleached and 
control ROI was obtained using the Analyze Particles function, while fluorescence of 
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particular EGFP–FMRP granules was measured using the linescan feature.  Data were 
exported into Microsoft Excel for subsequent analysis.  In some cases, cells were treated 
with arsenite 0.5 mM for 2 minutes prior to bleaching to induce stress granules.  Arsenite 
was maintained throughout the 20 minute FRAP time-lapse.  A total of five arsenite-
treated cells and five untreated cells were examined. 
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Legends 
Fig. 1. EGFP-FMRP granules are heterogeneous. (A) Confocal images of HeLa cells 
expressing EGFP-FMRP, EGFP, or endogenous FMRP.  (B) Size distribution of EGFP-
FMRP granules in HeLa cells.  Analysis was based on 9 transfected cells.  Note the three 
classes of granules (small, intermediate, large) based on size.  (C) Size distribution of 
endogenous FMRP granules.  Analysis was based on 27 cells.  Comparison of the two 
distributions shows that endogenous FMRP granules are significantly smaller 
(P<0.00084). 
Fig. 2. EGFP-FMRP granules partially colocalize with the stress granule marker 
TIA1.  Panels a-c show EGFP-FMRP (green), TIA1 (red) and merged images of 
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transfected PC12 cells.  Panels d-i show comparable images of transfected HeLa cells 
expressing EGFP-FMRP.   
Fig. 3. EGFP-FMRP granules partially colocalize with the stress granule marker 
FXR1P.  (A) Panels a-c show endogenous FRMP (green), endogenous FXR1P (red) and 
merged images of HeLa cells treated with 0.5 mM arsenite for 20 minutes.  Boxed areas 
show magnified views of select FMRP granules reveal the near complete colocalization 
of the granules.  (B) Panels d-f show EGFP-FMRP (green), endogenous FXR1P (red) and 
merged images of transfected HeLa cells.  Boxed areas show magnified views of select 
EGFP-FMRP granules.  White arrows mark FXR1P-only granules; yellow arrows mark 
colocalized granules and green arrows mark EGFP-FMRP-only granules.  (C) Panels g-i 
show EGFP-FMRP (green), endogenous FXR1P (red) and merged images of transfected 
HeLa cells treated with 0.5 mM arsenite for 20 minutes, 24 hours post-transfection.  
Boxed areas show magnified views of select EGFP-FMRP granules.  White arrows mark 
FXR1P-only granules; yellow arrows mark colocalized granules and green arrows mark 
EGFP-FMRP-only granules.   
Fig. 4. EGFP-FMRP granule formation does not require eIF2 phosphorylation. (A) 
Panels a-c show EGFP-FMRP (green), phospho-eIF2 (red) and merged images of 
transfected HeLa cells.  Boxed areas show magnified views of select EGFP-FMRP 
granules.  (B) Panels d-f show TIA1 (red), phospho-eIF2 (green) and merged images of 
HeLa cells treated with 0.5 mM arsenite for 20 minutes, 24 hours post-transfection.  
Boxed areas show magnified views of select TIA1 granules.  Yellow arrows mark 
colocalized granules and red arrows mark TIA1 stress granules.   
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Fig. 5. Hippurstanol treatment recruits EGFP-FMRP into stress granules.  (A) 
Panels a-c show EGFP-FMRP (green), TIA1 (red) and merged images of transfected 
HeLa cells treated with 10 M hippurstanol for 30 minutes, 24 hours post-transfection.  
Boxed areas show magnified views of select EGFP-FMRP granules.  Yellow arrows 
show colocalizing granules.  Panels d-f show comparable images of EGFP-FMRP 
(green), phospho-eIF2 (red) and merged images of transfected HeLa cells treated with 
10 M hippurstanol for 30 minutes, 24 hours post-transfection.  Boxed areas show 
magnified views of select EGFP-FMRP granules.  Green arrows show non-colocalized 
granules.  (B) Panels g-i show EGFP-FMRP (green), TIA1 (red) and merged images of 
transfected untreated HeLa cells.  Boxed areas show magnified views of select EGFP-
FMRP granules.  Yellow arrows show colocalizing granules.  Panels j-l show comparable 
images of EGFP-FMRP (green), phospho-eIF2 (red) and merged images of transfected 
untreated HeLa cells.  Boxed areas show magnified views of select EGFP-FMRP 
granules.  Yellow arrows show colocalizing granules green arrows show non-colocalized 
granules. 
Fig. 6. EGFP-FMRP granules partially colocalize with the P-body marker protein 
Dcp1a.  (A) Panels a-c show EGFP-FMRP (green), Dcp1a (red) and merged images of 
transfected untreated HeLa cells.  Boxed areas presented below show magnified views of 
select EGFP-FMRP granules.  Red arrows mark Dcp1a-only granules; yellow arrows 
mark colocalized granules and green arrows mark EGFP-FMRP-only granules.  (B) 
Panels d-f show comparable images of transfected HeLa cells treated with 0.5 mM 
arsenite for 20 minutes, 24 hours post-transfection.  Boxed areas presented below show 
magnified views of select EGFP-FMRP granules.  Red arrows mark Dcp1a-only 
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granules; yellow arrows mark colocalized granules and green arrows mark EGFP-FMRP-
only granules.  (C) Panels g-i show TIA1 (green), Hsp70 (red) and merged images of 
transfected untreated HeLa cells.  Panels j-l show comparable images of transfected HeLa 
cells treated with 0.5 mM arsenite for 20 minutes, 24 hours post-transfection.  Boxed 
areas presented below show magnified views of select stress granules.  Red arrows mark 
Hsp70-only granules; yellow arrows mark colocalized granules and green arrows mark 
TIA1-only granules.   
Fig. 7. Endogenous TIA1 and endogenous FMRP stress granules respond to 
emetine.  (A) Panels a-d show endogenous TIA1 (red), endogenous FMRP (green) HeLa 
cells treated with 0.5 mM arsenite for 20 minutes or treated with 0.5 mM arsenite and 
then 10 g/ml of emetine for 1 hour.  Boxed areas presented below show magnified 
views of select stress granules.  Size distribution of HeLa cell endogenous (B) TIA1 (C) 
endogenous FMRP stress granules in the presence and absence of emetine.  Analysis was 
based on 10 cells for each protein.  Comparison of the two distributions shows that 
emetine significantly reduces the size of both classes of stress granules (P<0.049 and P< 
4.5x10
-6
, respectively).   
Fig. 8. EGFP-FMRP granules respond to emetine.  (A) Panels a-d show EGFP-FMRP 
granules (green) in untreated HeLa cells (a, b) or HeLa cells treated with 0.5 mM arsenite 
for 20 minutes or treated with 0.5 mM arsenite and then 10 g/ml of emetine for 1 hour 
(c, d).  All treatments were performed 24 hours post-transfection.  Boxed areas presented 
below show magnified views of select stress granules.  Size distribution of HeLa cell 
EGFP-FMRP granules in the absence or presence of emetine and in the (B) absence or 
(C) presence of arsenite.  Analysis was based on 10 transfected cells for each protein.  
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Comparison of the two distributions shows that emetine significantly reduces the size of 
both classes of stress granules (P< 0.00084 and P< 0.0023, respectively).   
Fig. 9. EGFP-FMRP granules are dynamic.  (A) Pseudo colored image of EGFP-
FMRP expressing HeLa cell.  White box shows a region of interest (ROI) prior to 
photobleaching, while the yellow boxes show comparable ROIs of unbleached EGFP-
FMRP granules.  Arrows point to a granule that was photobleached (PB) and a nearby 
control granule (Ctrl) that was not.  (B) Time-dependent changes in the intensity of the 
ROIs shown in (A).  (C)  Time-dependent changes in PB (upper) and Ctrl (lower) 
granules shown in (A).  (D) Effect of arsenite treatment on EGFP-FMRP photobleaching 
recovery rates.  The intensity at time 0 for 25 non-bleached EGFP-FMRP granules, 23 
arsenite-treated photobleached EGFP-FMRP granules and 39 photobleached untreated 
EGFP-FMRP granules from 5 different cells was plotted.  The difference between the 
photobleached arsenite-treated granules was not significantly different from the untreated 
granules (P>0.2, ANOVA).  For presentation clarity error bars are shown on every third 
time point. 
Fig. 10. EGFP-FMRP granules contain asymmetrically dimethylated proteins. (A) 
HeLa cells expressing EGFP-FMRP were immunostained with antibodies directed to 
asymmetrically dimethylated proteins.  Panels a-e show images of EGFP-FMRP (green), 
ASYM24 (red), and their merged counterpart whereas panels f-k show images of  EGFP-
FMRP (green), mRG (red), and their merged counterpart.  Panels l-m demonstrate lack of 
immunostaining in the absence of primary antibody.  As indicated, the cells were either 
treated or not treated with 20 M AdOx for 24 hour following transfection.  (B) 
Quantification of anti-ASYM24 pAb, anti-mRG pAb and anti-SYM10 immunostaining in 
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HeLa cells grown in the absence (-) or presence (+) of 20 M AdOx.  The fluorescence 
intensity of the individual cells was determined using the histogram function in Adobe 
Photoshop as previously described (Dolzhanskaya et al., 2006a).  The values for 50-75 
cells/antibody for each treatment are plotted.  The reduction in fluorescence intensity in 
the presence of AdOx was significantly less than in its absence (ASYM24 P< 5x10
-15
, 
mRG P< 4x10
-15
, SYM10 P< 5x10
-17
 ANOVA).  
Fig. 11. EGFP-FMRP granule expression does not require full protein methylation.  
(A) HeLa cells were either treated or not treated with 20 M AdOx for 24 hours prior to 
transfection.  Subsequently, the cells were transfected with pEGFP-FMRP and imaged 24 
hours later.  Note: AdOx was re-applied to the set of cells that were pre-treated with 
AdOx.  (B) Size distribution of HeLa cell arsenite-treated EGFP-FMRP granules in the 
presence and absence of AdOx.  Analysis was based on 10 transfected cells/treatment.  
Comparison of the two distributions shows that AdOx does not significantly reduce the 
size of EGFP-FMRP granules (P> 0.4).   
Fig. 12. EGFP-FMRP granules contain symmetrically dimethylated proteins.  (A) 
HeLa cells expressing EGFP-FMRP were immunostained with an antibody directed to 
symmetrically dimethylated proteins (sDMA), SYM10.  Panels a-f show images of 
EGFP-FMRP (green), sDMA (red), and their merged counterparts in untreated cells and 
cells treated with 20 M AdOx for 24 hours following transfection.  Panels g-l show cells 
comparably treated cells that were either treated or not treated with 0.5 mM arsenite for 
20 minutes, 24 hours post-transfection. (B) Boxed areas from (A) show magnified views 
of select cells; yellow arrows mark colocalizing granules, green arrows mark EGFP-
FMRP only granules and red arrows mark sDMA only granules. 
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Fig. 13. AdOx inhibits cellular methylation of proteins that colocalize in EGFP-
FMRP granules.  Representative Western blots of HeLa cell proteins (30 g) probed 
with antibodies directed to methylated proteins, ASYM24 pAb (left) and SYM10 pAb 
(right), protein arginine methyltransferases (PRMTs) 1, 3, 4, and 5 and various load 
controls.   
Fig. 14. Endogenous TIA1 stress granules contain sDMA proteins.  HeLa cells were 
treated with 0.5 mM sodium arsenite (panels a-c) or not treated panels (e-g).  
Subsequently, the cells were immunostained with antibodies that detect the stress granule 
marker TIA1 (red) and SYM10 (green) and subject to confocal microscopy.  Magnified 
views of select regions of the upper panels are presented below to clearly show the 
granules.  Large TIA1-containing stress granules that colocalize with symmetrically 
dimethylated proteins are marked with yellow arrows.  These are contrasted with smaller 
granules harboring symmetrically dimethylated proteins, but which do not colocalize 
with TIA1 (green arrows).  Note that these smaller granules are constitutively present in 
untreated cells. We speculate that these may be related to the 7S PRMT5 complex, the 
20S methylosome or the SMN complex. 
Fig. 15.  Stress granules, EGFP-FMRP granules and endogenous FMRP granules do 
not contain SmD3.  HeLa cells (A, B) and HeLa cells expressing EGFP-FMRP (C) were 
treated or not treated with 0.5 mM sodium arsenite, 24 hours post-transfection.  
Subsequently, the cells were immunostained with antibodies to FMRP (panels a, d), TIA1 
(panels g, j) and SmD3 (panels b, e, h, k, n, q) and subject to confocal microscopy.  
Magnified views of select regions of the upper panels are presented below to clearly 
show the granules.  In none of cases do SmD3 granules and the other markers truly 
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colocalize; however, in the arsenite treatments smaller SmD3 granules appear to be 
associated with some of the larger stress granules (yellow arrows). 
Fig. 16. Stress granules, EGFP-FMRP granules and endogenous FMRP granules do 
not contain SmB/B’.  HeLa cells (A, B) and HeLa cells expressing EGFP-FMRP (C) 
were treated or not treated with 0.5 mM sodium arsenite for 20 minutes.  Subsequently, 
the cells were immunostained with antibodies to FMRP (panels a, d), TIA1 (panels g, j) 
and SmB/B’ (panels b, e, h, k, n, q) and subject to confocal microscopy.  Magnified 
views of select regions of the upper panels are presented below to clearly show the 
granules.  In none of cases do SmB/B’ granules and the other markers colocalize. 
Fig. 17. PRMT3 colocalizes with FXR1P-containing stress granules.  HeLa cells were 
treated for 20 minutes with 0.5 mM sodium arsenite, other cells were treated 24 hours 
with 10 M AdOx, followed by 20 minutes with 0.5 mM sodium arsenite or left 
untreated.  Subsequently, the cells were immunostained with an antibody that detects the 
stress granule marker FXR1P (red) and one that detects PRMT3 (green) and subject to 
confocal microscopy.  FXR1P stress granules that colocalize with PRMT3 are indicated 
with yellow arrows. 
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Table 1. EGFP-FMRP Colocalization Analysis 
Pair Treatment tM1d tM2d 
EGFP-FMRP/TIA1 None 0.069 (0.015) 0.057 (0.021) 
 AdOxa 0.068 (0.023) 0.061 (0.007) 
 Arseniteb 0.521 (0.014) † 0.449 (0.027) † 
 Hippurstanolc 0.228 (0.028) † 0.373 (0.003) † 
EGFP-FMRP/Dcp1a None 0.024 (0.014) 0.007 (0.003) 
 AdOxa 0.029 (0.011) 0.006 (0.003) 
 Arseniteb 0.028 (0.003) 0.010 (0.005) 
 Hippurstanolc 0.111 (0.045) † 0.126 (0.047) † 
a. Treatment with 10 M AdOx for 24 hrs prior to analysis. 
b. Treatment with 0.5 mM sodium arsenite for 20 min. prior to analysis. 
c. Treatment with 10 M hippurstanol for 30 min. prior to analysis. 
d. Thresholded Manders coefficients (Bolte and Cordelieres, 2006) for 
EGFP-FMRP granules, tM1 and tM2 were calculated using the JaCoP 
module in Image J.  The means and standard deviations, shown in 
parentheses, for at least 25 transfected cells per treatment are 
presented; fluorescence from non-transfected cells in the field was 
manually masked in order to examine only the colocalization of EGFP-
FMRP transfected cells.   
†Treatment is significantly different from non-treated (P>0.005, 
ANOVA). 
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 Table 2. Physical Characteristics of EGFP-FMRP Granules 
Measure/Granule EGFP-FMRP Stress Granulesc Stress Granulesd P-bodiese 
Circularitya 0.87 (0.2)† 0.91 (0.15) 0.91 (0.14) 0.95 (0.13) 
Areab 16.2 (47) ‡ 13.8 (29) 14.4 (19) 4.4 (8) 
a. Circularity measures the deviation of the granule from a perfect circle, scored as 1; the mean and (standard 
deviation) are shown. 
b. Area is given in squared pixels; the mean and (standard deviation) are shown. 
c. HeLa cell arsenite-induced TIA1 granules. 
d. HeLa cell hippurstanol-induced TIA1 granules. 
d. HeLa cell endogenous Dcp1a granules. 
† Circularity of 1000 EGFP-FMRP granules was significantly different from that of 1000 arsenite-induced 
granules, hippurstanol-induced granules and 1200 endogenous P-bodies (P<1x10-32, ANOVA). 
‡Area of 1000 EGFP-FMRP granules was significantly different from that of 1000 arsenite-induced granules, 
1000 hippurstanol-induced granules and 1200 endogenous P-bodies (P<6x10-19, ANOVA). 
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